8-K
filed May 12, 2026, 7:20 AM ET
ticker ACHV
CIK 0000949858
earnings
confidence high
sentiment negative
materiality 0.85
Q1 cash $29.3M; closed $180M upfront financing; expects CRL by June 20, 2026; new CEO appointed
ACHIEVE LIFE SCIENCES, INC.
2026-Q1 EPS
reported -$0.19
vs consensus -$0.31
▲ beat
(+39.6%)
- Q1 cash, equivalents, and marketable securities $29.3M; net loss $10.2M, operating expenses $10.5M.
- Closed private placement of up to $354M ($180M upfront + $174M milestone warrants).
- Andrew D. Goldberg, MD appointed CEO and board member; Christopher Martin added as director.
- Expects CRL from FDA by June 20, 2026; to resubmit NDA in Q4 2026 with new manufacturer Adare.
- Jaime Xinos departs as CCO May 31; Lucian Iancovici becomes Chair; Tom King steps down June 8.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ACHIEVE LIFE SCIENCES, INC. reported financial results for the first quarter of 2026.
- Period
- the first quarter of 2026
- Result
- reported results
Exact text from the filing
today announced financial results for the first quarter of 2026
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ACHIEVE LIFE SCIENCES, INC. reported financial results for the first quarter ended March 31, 2026.
- Period
- the first quarter ended March 31, 2026
- Result
- reported results
Exact text from the filing
On May 12, 2026, Achieve Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ACHIEVE LIFE SCIENCES, INC. reported the three months ended March 31, 2026 results: net income $10.2 million.
- Period
- the three months ended March 31, 2026
- Net income
- $10.2 million
- Result
- reported results
Exact text from the filing
Total operating expenses and net loss for the three months ended March 31, 2026 were $10.5 million and $10.2 million, respectively
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas King resigned as Chairman of the Board and Member at ACHIEVE LIFE SCIENCES, INC..
- Action
- resigned
- Role
- Chairman of the Board and Member
Exact text from the filing
Thomas King informed the Board that he has elected to resign from his position as a member and as chairman of the Board, effective as of June 8, 2026.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jaime Xinos departed as Chief Commercial Officer at ACHIEVE LIFE SCIENCES, INC..
- Action
- departed
- Role
- Chief Commercial Officer
Exact text from the filing
Jaime Xinos, the Company’s Chief Commercial Officer, will depart the Company, effective as of May 31, 2026.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lucian Iancovici was appointed as Chair of the Board at ACHIEVE LIFE SCIENCES, INC..
- Action
- appointed
- Role
- Chair of the Board
Exact text from the filing
Lucian Iancovici, MD, was appointed as Chair of the Board, effective as of June 8, 2026.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christopher Martin was appointed as Director at ACHIEVE LIFE SCIENCES, INC..
- Action
- appointed
- Role
- Director
Exact text from the filing
appointed Christopher Martin to serve as a director of the Company, effective immediately.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.